Octapharma AG
LACHEN, Switzerland, February 16 - Octapharma AG today announced the start of the first of a series of Phase
III studies for its new 10% high purity intravenous immunoglobulin (IVIG).
LACHEN, Switzerland, January 13 - Octapharma AG, one of the largest plasma products manufacturers in the
world, today announced that it has received orphan exclusivity approval for
wilate(R) from the U.S.
LACHEN, Switzerland -
- With Photo
Through June 2009, Octapharma AG realized a record turnover of 536 M euro, compared to 422 M euro as of year-to-date June 2008, an increase of 27%.
LACHEN, Switzerland and HOBOKEN, New Jersey -
- ISTH Symposia Discuss Prevention and Eradication of FVIII Inhibitors and Introduce First Recombinant FVIII Produced From a Human Cell Line
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors.
